A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy

A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy

Abstract The lysosome-targeting chimera (LYTAC) strategy provided a very powerful tool for the degradation of membrane proteins. However, the synthesis of LYTACs, antibody-small molecule conjugates, is challenging. The ability of antibody-based LYTACs to penetrate solid tumor is limited as well, esp...

Full description

Bibliographic Details
Main Authors: Youmei Xiao, Zhuoying He, Wanqiong Li, Danhong Chen, Xiaoshuang Niu, Xin Yang, Wenxuan Zeng, Mengfan Wang, Yuzhen Qian, Ye Su, Feiyu Luo, Guanyu Chen, Juan Liu, Xinghua Sui, Xiuman Zhou, Yanfeng Gao
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-56648-6

Internet

https://doi.org/10.1038/s41467-025-56648-6

Similar Items